What GRAIL, Inc. does.

We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw. Galleri has detected some of the most aggressive cancers in early stages including, among others, endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers. We have conducted what we believe is the largest clinical program in genomic medicine to date with data from over 385,000 participants that we believe demonstrate the clinical validation and clinical utility of Galleri in its intended use population. We have deep operational experience with over 800,000 tests processed across this clinical program and from our commercial experience, including through partnerships with leading healthcare systems, employers, digital health platforms, payors, and life insurance providers.

Revenue and profit, by fiscal year.

More on GRAL.

• GRAIL, Inc. summary
• GRAIL, Inc. financial statements
• GRAIL, Inc. key metrics
• GRAIL, Inc. health scores and style box
• GRAIL, Inc. earnings
• GRAIL, Inc. dividends
• GRAIL, Inc. valuation
• GRAIL, Inc. ownership and insiders
• GRAIL, Inc. peers

Figures from GRAIL, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.